Does peripheral quantitative computed tomography (pQCT) measures contribute to the understanding of bone fragility in older patients with low-trauma fracture?

Status

Not yet recruiting

Phases

Unknown

Study type

Observational

Source

ANZCTR

Registry ID

ACTRN12614001029684

Enrollment

Registered

2014-09-24

Start date

2014-09-25

Completion date

2015-08-31

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

Dual-energy X-ray absorptiometry (DXA) is well established to assess bone strength in clinical settings; however, it has many limitations. This research aims to evaluate the role of peripheral quantitative computed tomography (pQCT), an alternative bone density testing method that is believed to provide more information than DXA, for the assessment of bone strength. We will recruit patients with osteoporotic fracture and evaluate whether pQCT measures are associated with bone strength. We have already obtained normal pQCT measures in healthy young adults and calculated the means and standard deviations. We will compare patients’ pQCT results with the normal values to achieve our research aim. We may also find new factors that may contribute to fracture prediction in older patients.

Interventions

We will recruit patients with osteoporotic fracture presenting to outpatients clinic. The patients will have peripheral quantitative computed tomography (pQCT) test besides the routine dual-energy x-ray absorptiometry (DXA) test during one one-hour site visit. This is a cross-sectional study and all the patients will only have one site visit. DXA is a routine test for patients with low-trauma fracture. Patients will still have DXA examinations even if they don't participate in this project.

Eligibility

Sex/Gender

All

Age

50 Years to No maximum

Healthy volunteers

Inclusion criteria

1. Aged 50 years or greater; 2. One or more low-trauma fractures within the past three months; 3. Informed verbal and written consent provided.

Exclusion criteria

1. Prior diagnosis of osteoporosis; 2. Prolonged (>3 months) use of osteoporosis therapy in the past 2 years; 3. Prior therapy with teripatratide or strontium ranelate; 4. Unstable doses of hormone replacement therapy; 5. Patients with secondary causes of low bone density, e.g. hyperthyroidism, diabetes, Vitamin D deficiency, alcoholism, smoking.

Outcome results